卿氏湿疹疱洗方2号治疗血虚风燥型手足慢性湿疹临床疗效观察

目的:探讨卿氏湿疹泡洗方2号对血虚风燥型手足慢性湿疹的效果。方法:选取我院2018年1月-2018年9月血虚风燥型手足慢性湿疹患者116例,根据治疗方案不同分为研究组(58例)和参照组(58例),参照组给予卤米松乳膏联合尿素乳膏,研究组给予卿氏湿疹疱洗方2号联合尿素乳膏,比较两组治疗效果、治疗前后湿疹面积及严重度指数(Eczema Area and Severity Index,EASI)、皮肤病生活质量指数(Dermatology life uality Index,DLQI)及不良反应。结果:研究组治疗总有效率为94.83%(55/58),高于参照组82.76%(48/58)(P<0.05);两组治疗后EASI、DLQI评分均低于治疗前,且研究组低于参照组(P<0.05);两组均未见严重不良反应。结论:卿氏湿疹泡洗方2号治疗血虚风燥型手足慢性湿疹患者疗效确切,可明显改善临床症状,缩小湿疹面积,提高患者生活质量,且不增加不良反应,安全性高,值得临床推广应用。     

复方亚甲蓝局部封闭联合中医药治疗肛周湿疹有效性和安全性的Meta分析

目的:系统评价复方亚甲蓝局部封闭联合中医药治疗肛周湿疹的有效性和安全性。方法:计算机检索中国知网(CNKI),维普中文期刊数据库(VIP),万方数字化期刊全文数据库,中国生物医学文献数据库,Embase,PubMed,Cochrane Library,收集复方亚甲蓝局部封闭联合中医药治疗肛周湿疹的临床随机对照研究,检索时限均为从建库至2019年5月。采用RevMan.5.3软件进行数据分析。结果:共纳入22个随机对照试验,共计2211例肛周湿疹患者。Meta分析显示:与常规治疗组相比,复方亚甲蓝局部封闭联合中医药治疗肛周湿疹在提高有效率、改善症状(瘙痒程度、渗出潮湿、皮损面积、皮损形态),降低症状体征总积分、减少复发率具有明显意义(P<0.05),但对于提高患者的生活质量意义不大(P=0.37>0.05);对降低不良反应发生率方面无明显意义(P=0.41>0.05),未见复方亚甲蓝局部封闭联合中药应用严重不良反应报道。结论:基于目前检索的文献及Meta分析结果,复方亚甲蓝局部封闭联合中医药治疗肛周湿疹的疗效在一定程度上优于常规疗法。但由于纳入研究的方法学质量偏低,证据质量低,临床治疗中可以借鉴应用,但仍需高质量的随机对照试验(Randomized Controlled Trial,RCT)进行验证。     

Atopic dermatitis without serum immunoglobulin E elevation or loss-of-function filaggrin gene mutation in a patient with X-linked agammaglobulinemia

A case of atopic dermatitis (AD) with X-linked agammaglobulinemia (XLA), which is one of the primary immunodeficiency diseases, is reported. A 12-year-old boy had suffered from dry skin and recurrent itchy eruptions since he was 2 years old, and he was diagnosed as having XLA at the age of 4 years. His total immunoglobulin (Ig)E level was 7 IU/mL, even with regular Ig replacement therapy. Furthermore, filaggrin (FLG) mutations known in the Japanese population were not found. His skin lesions were well controlled by the application of a mild-class topical steroid and a moisturizer, though he developed folliculitis due to Staphylococcus aureus infection during treatment with a strong-class topical steroid. This case suggests that the FLG mutation and IgE-mediated sensitization are not necessary to induce AD skin manifestation.     

Atenolol oral en el manejo del hemangioma infantil: serie de casos de 46 pacientes

Propranolol, a non-selective beta-blocker, remains the first line of treatment for problematic infantile hemangioma. However, although rarely, a subset of patients experience undesirable side effects, raising interest in other selective beta-blockers. We present a large case series of 46 infants treated successfully with oral atenolol, a selective beta-1 blocker.